Trial Profile
Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2021
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms IRENO
- 27 Aug 2020 Status changed from active, no longer recruiting to completed.
- 03 Apr 2020 Planned primary completion date changed from 1 Feb 2020 to 1 Dec 2020.
- 19 Jul 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Feb 2020.